Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by JayjayUSA12007on Apr 02, 2018 10:53pm
137 Views
Post# 27818368

RE:Medical Mutual ask resistance to three drugs in three classe

RE:Medical Mutual ask resistance to three drugs in three classeQuote:
"Multi-drug Resistant HIV-1 Infection. Criteria.  
The patient must meet the following criteria (a, b, c, d AND e):
a)The patient is at least 18 years of age; AND
b)Trogarzo is prescribed by or in consultation with an infectious diseases physician or a physician who specializes
in the treatment of HIV infections; AND
c)The patient has been diagnosed with multi-drug resistant HIV-1 infection and meets the following criteria (i and
ii):
i.Patient has been adherent to treatment with antiretrovirals for at least 6 months and are failing or recently failed therapy; AND
ii.Patient has documented resistance to at least one antiretroviral medication from each of three classes of antiretroviral medications (NRTI, NNRTI, and PI) as measured by resistance testing (i.e. genotype and phenotype) [documentation required]; AND
d)The patient has a RNA viral load greater than 1,000 copies/mL [documentation required]; AND
e)Trogarzo will be used in combination with other antiretroviral medications."

This company policy is clearly against FDA label.  When HIV patients are denied of this treatment, they will sue this company to bankruptcy ! This will be a disaster waiting to happen.

Bullboard Posts